13011-62-6 Purity
---
If you have any other questions or need other size, please get a quote.
Specification
3-Hydrazinoquinoxaline-2-thiol is a quinoxaline derivative. In this work, the fungicidal activity of 3-hydrazinoquinoxaline-2-thiol against Candida albicans was investigated. The results showed that 3-hydrazinoquinoxaline-2-thiol demonstrated greater efficacy than Amphotericin B against the majority of clinical isolates of Candida albicans, particularly showing enhanced effectiveness against isolates of Candida glabrata and Candida parapsilosis. Additionally, 3-hydrazinoquinoxaline-2-thiol proved to be effective against Pichia kudriavzevii and Clavispora lusitaniae. In a mouse model, it exhibited significant efficacy against C. albicans ATCC 10231 cells.
Preparation of 3-hydrazinoquinoxaline-2-thiol gel formulation
· To prepare a 1% hydrogel of 3-hydrazinoquinoxaline-2-thiol, 2 grams of hydroxypropyl methylcellulose (HPMC) was placed in a suitable beaker and combined with 50 ml of purified hot water to allow for soaking.
· Following this, 10 ml of glycerol was incorporated, and the mixture was allowed to soak further. The beaker was then covered and left at room temperature for 24 hours to facilitate gel formation.
· To create the hydrogel containing 1% w/w of 3-hydrazinoquinoxaline-2-thiol, 1 gram of the compound was dissolved in 5 milliliters of 99% methanol and 35 ml of distilled water. This drug solution in methanol was incrementally mixed into 45 grams of the plain HPMC gel while continuously stirring gently to achieve a uniform gel consistency.
A 3-hydrazinoquinoxaline-2-thiol hydrogel was prepared and evaluated for its wound healing effect on full-thickness excisional wounds in streptozotocin-induced type 1 diabetic rats. The results showed that wound closure was significantly accelerated and epithelialization and collagen deposition were enhanced in the treatment group. Furthermore, a significant decrease in the levels of proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and NF-κB, as well as an increase in TGFβ-1 levels, was observed. Overall, 3-hydrazinoquinoxaline-2-thiol has the ability to enhance wound contraction, promote epithelialization, and modulate inflammatory mediators.
Preparation procedure of 3-hydrazinoquinoxaline-2-thiol hydrogel
· A 2% (w/w) hydroxypropyl methylcellulose (HPMC) gel was created by dissolving 3 g of HPMC in distilled water until the total weight reached 100 g. The mixture was then covered and gently stirred with a magnetic stirrer, allowing it to sit for 24 hours to facilitate complete water absorption and gel formation.
· To prepare the 0.2% hydrogel, 0.2 g of the 3-hydrazinoquinoxaline-2-thiol was mixed with 2 g of dimethyl sulfoxide (DMSO), and this solution was gradually combined with 98 g of the 3% HPMC gel while stirring continuously to ensure the drug was uniformly dispersed within the gel matrix.
· The same method was used to create a control sample. Finally, the gel was placed into collapsible tubes and stored in a cool, dry environment.
The molecular formula of 3-hydrazinoquinoxaline-2-thiol is C8H8N4S.
The molecular weight of 3-hydrazinoquinoxaline-2-thiol is 192.24 g/mol.
Another name for 3-hydrazinoquinoxaline-2-thiol is 3-hydrazinylquinoxaline-2-thiol.
The IUPAC name of 3-hydrazinoquinoxaline-2-thiol is 3-hydrazinyl-1H-quinoxaline-2-thione.
The InChI of 3-hydrazinoquinoxaline-2-thiol is InChI=1S/C8H8N4S/c9-12-7-8(13)11-6-4-2-1-3-5(6)10-7/h1-4H,9H2,(H,10,12)(H,11,13).
The InChIKey of 3-hydrazinoquinoxaline-2-thiol is TVYAHCDRRICQJM-UHFFFAOYSA-N.
The CAS number of 3-hydrazinoquinoxaline-2-thiol is 13080-21-2.
The XLogP3-AA value of 3-hydrazinoquinoxaline-2-thiol is 0.4.
3-hydrazinoquinoxaline-2-thiol has 3 hydrogen bond donor counts.
The topological polar surface area of 3-hydrazinoquinoxaline-2-thiol is 94.5Ų.
Reference: [1]Location in patent: experimental part
Kulkarni, Naveen V.; Bevinahalli, Nagaraj H.; Revankar, Vidyanand K.
[Journal of Coordination Chemistry, 2010, vol. 63, # 10, p. 1785 - 1794]
[2]Location in patent: experimental part
Kulkarni, Naveen V.; Kurdekar, Gurunath S.; Budagumpi, Srinivasa; Revankar, Vidyanand K.
[Journal of Coordination Chemistry, 2010, vol. 63, # 18, p. 3301 - 3312]
[3]Asano et al.
[Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1959, vol. 79, p. 24,27][Chem.Abstr., 1959, p. 10242]
[4]Location in patent: experimental part
Kurdekar, Gurunath S.; Kulkarni, Naveen V.; Budagumpi, Srinivasa; Sathisha; Bevinhalli, Nagaraj H.; Revankar, Vidyanand K.
[Journal of Coordination Chemistry, 2010, vol. 63, # 12, p. 2172 - 2180]